A decade of progress in kidney transplantation.
Kidney transplantation has become the treatment of choice for patients with end-stage renal disease because of better surgical techniques and the availability of more powerful immunosuppressive drugs. Regimens of immunosuppression should combine both short-term outcomes and predictors of long-term safety and survival. The value of tacrolimus for immunosuppression protocols lies in its ability to reduce the immunologic risk to the allograft and its excellent safety profile. Outcomes for kidney-transplant recipients can be further optimized by individualizing therapy to address each patient's risk profile.
Vincenti
Flavio
F
University of California-San Francisco, San Francisco, CA 94143, USA.
D002318:Cardiovascular Diseases / Q000209:etiology; D003920:Diabetes Mellitus / Q000209:etiology; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016559:Tacrolimus